# US 11,298,347 B2 · Methods of diagnosing and treating Tourette syndrome > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,298,347 B2 - Document ID: US11298347B2 - Status: Granted - Kind: B2 - Application number: 16/809,045 - Filed: 2020-03-04 - Published: 2020-10-01 - Granted: 2022-04-12 - Earliest claimed: 2015-09-08 - Assignees: The Children's Hospital of Philadelphia - Applicants: The Children's Hospital of Philadelphia - Inventors: Hakon Hakonarson; Charlly Kao - Web page: https://patentgrep.com/patent/US11298347B2 ## CPC - A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/22: Anxiolytics - C12Q 1/6883: for diseases caused by alterations of genetic material - C12Q 2600/156: Polymorphic or mutational markers - C12Q 2600/158: Expression markers - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES ## Abstract Methods and uses for diagnosing and treating Tourette syndrome are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam. ## Claims ### Claim 1 A method for treating Tourette syndrome (TS) in a subject comprising (a) isolating a sample comprising nucleic acid from a subject that has TS, (b) detecting at least one CNV in a mGluR network gene of the subject, (c) administering an effective amount of fasoracetam to the subject with the at least one CNV in a mGluR network gene, and (d) assessing the subject for a reduction in tic symptoms following at least 4 weeks of treatment with fasoracetam. ### Claim 2 (depends on 1) The method of claim 1, wherein the CNV is a duplication or deletion. ### Claim 3 (depends on 1) The method of claim 1, wherein fasoracetam is fasoracetam monohydrate. ### Claim 4 (depends on 1) The method of claim 1, wherein the subject has a CNV in at least 2 mGluR network genes. ### Claim 5 (depends on 1) The method of claim 1, wherein the subject does not have a CNV in any of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7, or GRM8. ### Claim 6 (depends on 1) The method of claim 1, wherein the tic symptoms comprises frequency and/or degree of movement. ### Claim 7 (depends on 1) The method of claim 1, wherein the subject also has obsessive compulsive disorder (OCD). ### Claim 8 (depends on 7) The method of claim 7, wherein the symptoms of OCD are reduced in the subject following at least 4 weeks of treatment with the fasoracetam. ### Claim 9 (depends on 1) The method of claim 1, wherein detecting at least one CNV in a mGluR network gene comprises subjecting the sample to a screen that assesses CNVs in at least 5 Tier 1 mGluR network genes. ### Claim 10 (depends on 1) The method of claim 1, wherein detecting at least one CNV in a mGluR network gene comprises subjecting the sample to a screen that assesses CNVs in at least 50 Tier 2 mGluR network genes. ### Claim 11 (depends on 1) The method of claim 1, wherein the TS is one or more of persistent (chronic) motor tic disorder, persistent (chronic) vocal tic disorder, or provisional tic disorder. ### Claim 12 (depends on 1) The method of claim 1, wherein the subject is a pediatric or adolescent subject. ### Claim 13 (depends on 12) The method of claim 12, wherein the pediatric or adolescent subject is between the ages of 12 and 18. ### Claim 14 (depends on 1) The method of claim 1, wherein the subject also has schizophrenia. ### Claim 15 (depends on 1) The method of claim 1, wherein the subject has at least one CNV in a Tier 1 mGluR network gene. ### Claim 16 (depends on 1) The method of claim 1, wherein the subject has at least one CNV in a Tier 2 mGluR network gene. ### Claim 17 (depends on 1) The method of claim 1, wherein the subject has at least one CNV in a Tier 1 or a Tier 2 mGluR network gene but does not have a CNV in Tier 3 mGluR network gene. ### Claim 18 (depends on 1) The method of claim 1, wherein fasoracetam is administered at a dose of 100-400 mg twice daily. ### Claim 19 (depends on 1) The method of claim 1, wherein fasoracetam is administered at a dose of 200-400 mg twice daily.